Cargando…
Dopamine Agonists and Pathologic Behaviors
The dopamine agonists ropinirole and pramipexole exhibit highly specific affinity for the cerebral dopamine D3 receptor. Use of these medications in Parkinson's disease has been complicated by the emergence of pathologic behavioral patterns such as hypersexuality, pathologic gambling, excessive...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328150/ https://www.ncbi.nlm.nih.gov/pubmed/22567537 http://dx.doi.org/10.1155/2012/603631 |
_version_ | 1782229700589912064 |
---|---|
author | Kelley, Brendan J. Duker, Andrew P. Chiu, Peter |
author_facet | Kelley, Brendan J. Duker, Andrew P. Chiu, Peter |
author_sort | Kelley, Brendan J. |
collection | PubMed |
description | The dopamine agonists ropinirole and pramipexole exhibit highly specific affinity for the cerebral dopamine D3 receptor. Use of these medications in Parkinson's disease has been complicated by the emergence of pathologic behavioral patterns such as hypersexuality, pathologic gambling, excessive hobbying, and other circumscribed obsessive-compulsive disorders of impulse control in people having no history of such disorders. These behavioral changes typically remit following discontinuation of the medication, further demonstrating a causal relationship. Expression of the D3 receptor is particularly rich within the limbic system, where it plays an important role in modulating the physiologic and emotional experience of novelty, reward, and risk assessment. Converging neuroanatomical, physiological, and behavioral science data suggest the high D3 affinity of these medications as the basis for these behavioral changes. These observations suggest the D3 receptor as a therapeutic target for obsessive-compulsive disorder and substance abuse, and improved understanding of D3 receptor function may aid drug design of future atypical antipsychotics. |
format | Online Article Text |
id | pubmed-3328150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33281502012-05-07 Dopamine Agonists and Pathologic Behaviors Kelley, Brendan J. Duker, Andrew P. Chiu, Peter Parkinsons Dis Review Article The dopamine agonists ropinirole and pramipexole exhibit highly specific affinity for the cerebral dopamine D3 receptor. Use of these medications in Parkinson's disease has been complicated by the emergence of pathologic behavioral patterns such as hypersexuality, pathologic gambling, excessive hobbying, and other circumscribed obsessive-compulsive disorders of impulse control in people having no history of such disorders. These behavioral changes typically remit following discontinuation of the medication, further demonstrating a causal relationship. Expression of the D3 receptor is particularly rich within the limbic system, where it plays an important role in modulating the physiologic and emotional experience of novelty, reward, and risk assessment. Converging neuroanatomical, physiological, and behavioral science data suggest the high D3 affinity of these medications as the basis for these behavioral changes. These observations suggest the D3 receptor as a therapeutic target for obsessive-compulsive disorder and substance abuse, and improved understanding of D3 receptor function may aid drug design of future atypical antipsychotics. Hindawi Publishing Corporation 2012 2012-04-05 /pmc/articles/PMC3328150/ /pubmed/22567537 http://dx.doi.org/10.1155/2012/603631 Text en Copyright © 2012 Brendan J. Kelley et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Kelley, Brendan J. Duker, Andrew P. Chiu, Peter Dopamine Agonists and Pathologic Behaviors |
title | Dopamine Agonists and Pathologic Behaviors |
title_full | Dopamine Agonists and Pathologic Behaviors |
title_fullStr | Dopamine Agonists and Pathologic Behaviors |
title_full_unstemmed | Dopamine Agonists and Pathologic Behaviors |
title_short | Dopamine Agonists and Pathologic Behaviors |
title_sort | dopamine agonists and pathologic behaviors |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328150/ https://www.ncbi.nlm.nih.gov/pubmed/22567537 http://dx.doi.org/10.1155/2012/603631 |
work_keys_str_mv | AT kelleybrendanj dopamineagonistsandpathologicbehaviors AT dukerandrewp dopamineagonistsandpathologicbehaviors AT chiupeter dopamineagonistsandpathologicbehaviors |